Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Yakult Honsha, AEZS sign agreement to develop, commercialize and license perifosine

Aeterna Zentaris Inc. and Yakult Honsha Co., Ltd. today announced the signing of an exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for Japan.

9 Mar 2011

New study finds liver instead of the brain as source of Alzheimer’s plaques

Unexpected results from a Scripps Research Institute and ModGene, LLC study could completely alter scientists' ideas about Alzheimer's disease—pointing to the liver instead of the brain as the source of the "amyloid" that deposits as brain plaques associated with this devastating condition. The findings could offer a relatively simple approach for Alzheimer's prevention and treatment.

4 Mar 2011

Scientists provide new insight into mechanisms controlling programmed cell death pathways

Work led by St. Jude Children's Research Hospital investigators provides fresh insight into mechanisms controlling programmed cell death pathways and offers new targets in the fight against cancer and virus-infected cells

3 Mar 2011

New microfluidic device may help clinicians to improve cancer therapy

Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.

3 Mar 2011

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.

7 Feb 2011

OSC and RINCH offer support to speed discovery techniques of childhood diseases

Worried about her high fever and severe abdominal pain, a young couple rushed their baby daughter to the emergency department of Nationwide Children's Hospital. Physicians there found a lump in her belly, and, after examining X-rays and blood work, confirmed the parents' worst fear: their 18-month-old little girl had neuroblastoma, a rare pediatric cancer that involves the adrenal glands.

20 Jan 2011

Genetic information from Guthrie cards may serve as valuable resource to diagnose infant diseases

Van Andel Research Institute researchers have developed a method that can yield more information from archived newborn blood that has implications for a vast array of research, including population health studies and answering questions about diseases in infants and children.

13 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

The day when an ovarian cancer patient can treat her tumor with a single, painless pill instead of a toxic drug cocktail is the ultimate goal of the pioneering research of a University of Houston scientist.

22 Dec 2010

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

16 Dec 2010

Bioengineers explain why some neurons die sooner than others in brains of AD patients

Bioengineers from the University of California, San Diego developed an explanation for why some types of neurons die sooner than others in the brains of people with Alzheimer's disease. These insights, published in the journal Nature Biotechnology on November 21, come from detailed models of brain energy metabolism developed in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering.

8 Dec 2010

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.

7 Dec 2010

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.

6 Dec 2010

LMO1 gene variation can increase neuroblastoma risk

Pediatric cancer researchers have identified variations in a gene as important contributors to neuroblastoma, the most common solid cancer of early childhood. The study team, led by researchers at The Children's Hospital of Philadelphia, found that common variants in the LMO1 gene increase the risk of developing an aggressive form of neuroblastoma, and also mark the gene for continuing to drive the cancer's progression once it forms.

2 Dec 2010

Racial disparities in risk and survival among children with neuroblastoma: Study

Black, Asian, and Native American children are more likely than white and Hispanic children to die after being treated for neuroblastoma, according to new research on the pediatric cancer. The study, of more than 3,500 patients with the disease, is the largest ever to look at racial disparities in risk and survival for the most common solid cancer found in young children.

23 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

Enzon Pharmaceuticals, Inc. today announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company's novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma.

5 Oct 2010

Study shows immunotherapy improves survival rate in children with neuroblastoma

Using immunotherapy biologic agents that stimulate the body's immune system pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma. A newly released study shows that the new treatment improved two-year survival rates by 20 percent, compared to standard treatment for an aggressive form of neuroblastoma, a cancer of the nervous system.

30 Sep 2010

New form of immunotherapy increases survival in children with neuroblastoma

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.

30 Sep 2010

Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Yakult Honsha, AEZS sign agreement to develop, commercialize and license perifosine

New study finds liver instead of the brain as source of Alzheimer’s plaques

Scientists provide new insight into mechanisms controlling programmed cell death pathways

New microfluidic device may help clinicians to improve cancer therapy

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

OSC and RINCH offer support to speed discovery techniques of childhood diseases

Genetic information from Guthrie cards may serve as valuable resource to diagnose infant diseases

Study supports use of telomerase inhibitors for treatment of childhood cancers

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Bioengineers explain why some neurons die sooner than others in brains of AD patients

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

LMO1 gene variation can increase neuroblastoma risk

Racial disparities in risk and survival among children with neuroblastoma: Study

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Novel small molecule inhibitors may provide new therapy for colon cancer

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

Study shows immunotherapy improves survival rate in children with neuroblastoma

New form of immunotherapy increases survival in children with neuroblastoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in